Formononetin suppresses osteosarcoma by targeting MYO1B and remodeling the tumor immune microenvironment.

APL Bioeng · 2025 · PMC12757119 · PMID 41488589

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Compared to the control group, the proportion of the M1-like TAM_Il1b significantly increased in the FMN group, while the proportion of the M2-like TAM_Lyve1 showed a decreasing trend, along with a reduction in the TAM_Proli [ Fig. 7(c) ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.